Search


USFDA Guidance: Pharmacogenomic Data Submissions
Earlier today (16 March 2023) the US Food and Drug Administration's Center for Drug Evaluation and Research (CDER), Center for Biologics...

Sharan Murugan
Mar 17, 20231 min read
Â
Â


USFDA Guidance: Electronic Systems, e-Records, & e-Signatures in clinical Investigations: Q&A
A draft guidance from the US Food and Drug Administration entitled "Electronic Systems, Electronic Records, and Electronic Signatures in...

Sharan Murugan
Mar 16, 20231 min read
Â
Â


Swissmedic Guidance: Requesting Certificate of a Pharmaceutical Product (CPP)
Earlier today (13 March 2023) Switzerland's SwissMedic released an updated "Guidance document for requesting product certificates (CPP)"...

Sharan Murugan
Mar 13, 20231 min read
Â
Â


Malaysia NPRA: Declaration of WorldWide Registration Status for Generic Medicines in QUEST System
Yesterday (10 March 2023) released an updated word template that shall declare their worldwide registration status (WWRS) for all new...

Sharan Murugan
Mar 11, 20231 min read
Â
Â


EMA Guideline: Computerised Systems & Electronic Data in Clinical Trials
Recently (9 March 2023) the European Medicine agency released a "Guideline on Computerised Systems & Electronic Data in Clinical Trials"...

Sharan Murugan
Mar 11, 20231 min read
Â
Â


Philippines FDA: Guidelines on Regulatory Reliance on the Conduct of Clinical Trials
Yesterday (3rd March 2023) the Philippines Food and Drug Administration (FDA) released an updated guideline "Guidelines on Regulatory...

Sharan Murugan
Mar 4, 20231 min read
Â
Â


Swiss Medic Guidance: Product Information & Packaging for Human Medicinal Products
Recently (01 march, 2023) Swissmedic released an updated guidance document on "Product information for human medicinal products" and...

Sharan Murugan
Mar 4, 20231 min read
Â
Â


USFDA Guidance: CMC-Potency Assay Considerations for Monoclonal Antibodies & Therap. Protiens
Earlier today (01 March, 2023) USFDA released a draft guidance on "Potency Assay Considerations for Monoclonal Antibodies and Other...

Sharan Murugan
Mar 1, 20231 min read
Â
Â


ICH-Quality Guidance: Q13 Continuous Manufacturing of Drug Substances and Drug Products
In today's FDA press release, the ICH final guidance titled "Q13 Continuous Manufacturing of Drug Substances and Drug Products" was...

Sharan Murugan
Mar 1, 20231 min read
Â
Â


EMA Procedural Advice: Recommendations on Unforeseen Variations
Earlier today (27 February 2023) European Medicine agency released an updated "Procedural Advice on Recommendations on unforeseen...

Sharan Murugan
Feb 27, 20231 min read
Â
Â


USFDA Guidance: Product-Specific Guidance Meetings Between FDA and ANDA Applicants
The Food and Drug Administration published a new draft guidance for the industry on February 17, 2023, titled "Product-Specific Guidance...

Sharan Murugan
Feb 19, 20232 min read
Â
Â


Swiss Medic Guidance: Document on Formal requirements
Swissmedic released an updated guidance document on "Formal requirements" yesterday (15 February 2023). By publishing this document,...

Sharan Murugan
Feb 16, 20231 min read
Â
Â


EMA Checklist: Updated Validation checklist for Type II quality variations
Recently on 10th February 2023, the European Medicines Agency (EMA) updated and released their "Validation checklist for Type II quality...

Sharan Murugan
Feb 14, 20231 min read
Â
Â


Pakistan DRAP Guidance: GMP for Manufacturing Sites of Drugs
Earlier today (09-January-2022), the Drug Regulatory Authority of Pakistan released an updated guidance on "Good Manufacturing Practices...

Sharan Murugan
Feb 9, 20231 min read
Â
Â


South Africa's (SAPHRA) Guideline for Fixed-Dose Combination Products
Earlier today (07-February-2023) the South African Health Products Regulatory Authority (SAPHRA) released an updated "Guideline for...

Sharan Murugan
Feb 7, 20231 min read
Â
Â


Ireland's HPRA: Guide to Clinical Trial Applications
Recently in January, the Health Products Regulatory Authority (HPRA) of Ireland updated its guidance on "HPRA Guide to Clinical Trial...

Sharan Murugan
Feb 2, 20231 min read
Â
Â


Health Canada Guidance: Conduct and Analysis of Comparative Bioavailability Studies
Recently (30 January 2023) Health Canada updated their guidance document on "Conduct and Analysis of Comparative Bioavailability...

Sharan Murugan
Feb 1, 20231 min read
Â
Â


ICH (USFDA) Guidance: Bioequivalence for Immediate-Release Solid Oral Dosage Forms
The USFDA released draft guidance for the industry on January 31, 2023, “M13A Bioequivalence for Immediate-Release Solid Oral Dosage...

Sharan Murugan
Feb 1, 20231 min read
Â
Â


USFDA Guidance: Design and Conduct of Externally Controlled Trials for Drug and Biological Products
Earlier today, the FDA published a draft guidance for the industry titled, "Considerations for the Design and Conduct of Externally...

Sharan Murugan
Jan 31, 20231 min read
Â
Â


MHRA Guidance: Innovative Licensing and Access Pathway (updation)
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has updated its guidance information on the Innovative Licensing and...

Sharan Murugan
Jan 31, 20231 min read
Â
Â
